|
Recurrent optic neuritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we characterize clinical and neuroimaging findings in severe cases of MOG antibody-positive and AQP4 antibody-negative bilateral rON.
|
30015656 |
2019 |
|
Recurrent optic neuritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified four MOG antibody-positive patients with non-ON inflammatory ophthalmological presentations and present their detailed clinical information in this case series.
|
30748058 |
2019 |
|
Recurrent optic neuritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelin oligodendrocyte glycoprotein (MOG) antibodies have a strong association with acute disseminated encephalomyelitis (ADEM) in children, and bilateral and recurrent optic neuritis in children and adults.
|
30221764 |
2019 |
|
Recurrent optic neuritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Especially, patients of acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), aquaporin-4 (AQP4) seronegative neuromyelitis optica spectrum disorder (NMOSD), monophasic or recurrent optic neuritis (ON), transverse myelitis and N-methyl-d-aspartate (NMDA) receptor encephalitis (NMDARe) can overlap with Myelin Oligodendrocyte Glycoprotein antibodies.
|
30590238 |
2019 |
|
Recurrent optic neuritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subsequently, myelin oligodendrocyte glycoprotein (MOG) IgG was recognized to be a marker for MOG-IgG-associated disorder, a central demyelinating disease characterized by recurrent optic neuritis, prominent disk edema, and perineural optic nerve enhancement on magnetic resonance imaging.
|
31425702 |
2019 |
|
Recurrent optic neuritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab was effective for acute disseminated encephalomyelitis followed by recurrent optic neuritis with anti-myelin oligodendrocyte glycoprotein antibodies.
|
29661590 |
2018 |
|
Recurrent optic neuritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Over the past few years, new-generation cell-based assays have demonstrated a robust association of autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis and brainstem encephalitis, as well as with acute disseminated encephalomyelitis (ADEM)-like presentations.
|
29724224 |
2018 |
|
Recurrent optic neuritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The rON-only cohort comprised the following: double seronegative (idiopathic), 110 patients (59%); MOG IgG1 positive, 27 patients (15%; 4 with chronic relapsing inflammatory optic neuropathy); multiple sclerosis (MS), 25 patients (13%); and aquaporin-4 IgG positive, 24 patients (13%).
|
29716788 |
2018 |
|
Recurrent optic neuritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The characteristics of MOG antibody-positive RON were summarized.
|
30112048 |
2018 |
|
Recurrent optic neuritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified 17 patients with MOG Abs from our outpatient clinic and selected 2 with a cross-reactivity to rodent MOG; both had recurrent optic neuritis.
|
30014603 |
2018 |
|
Recurrent optic neuritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Antibodies against conformation-dependent epitopes of myelin-oligodendrocyte-glycoprotein (MOG-abs) are present in subgroups of neuromyelitis optica spectrum disorder (NMOSD), recurrent optic neuritis (rON), multiple sclerosis (MS), and anti-NMDAR encephalitis.
|
27844165 |
2017 |